Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 27, 2023

Lannett Company Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the competitive landscape for LANNETT, and what generic and branded alternatives to LANNETT drugs are available?

LANNETT has one hundred and forty-four approved drugs.

There is one tentative approval on LANNETT drugs.

Summary for Lannett

US Patents:	0
Tradenames:	106
Ingredients:	101
NDAs:	144
Patent Litigation for Lannett:	See patent lawsuits for Lannett
PTAB Cases with Lannett as petitioner:	See PTAB cases with Lannett as petitioner

Drugs and US Patents for Lannett

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride	TABLET;ORAL	212996-004	Jan 22, 2021	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
Lannett	BETHANECHOL CHLORIDE	bethanechol chloride	TABLET;ORAL	084702-001	Approved Prior to Jan 1, 1982		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
Lannett Co Inc	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	205022-001	Sep 19, 2016	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
Lannett Co Inc	TERBUTALINE SULFATE	terbutaline sulfate	TABLET;ORAL	077152-001	Mar 25, 2005	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Lannett

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lannett Co Inc	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for LANNETT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Colorcon

Express Scripts

Merck

McKesson

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.